Skip to main content
诺思兰德 logo

诺思兰德 — Investor Relations & Filings

Ticker · 920047 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 539 across all filing types
Latest filing 2022-05-17 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920047

About 诺思兰德

https://www.northland-bio.com/

Northland Biotech focuses on the research, development, and commercialization of gene therapies and recombinant protein pharmaceuticals. The company’s primary therapeutic areas include cardiovascular diseases, peripheral arterial diseases, and ophthalmology. Its core R&D pipeline features NL003, a hepatocyte growth factor gene therapy targeting critical limb ischemia, and NL005, a recombinant human thymosin beta 4 for treating myocardial ischemia. Beyond its innovative pipeline, the company maintains advanced manufacturing facilities for biologics and ophthalmic preparations, producing a range of specialized eye drops. By leveraging its proprietary technology platforms, Northland Biotech aims to provide effective treatments for chronic and degenerative conditions through advanced molecular medicine.

Recent filings

Filing Released Lang Actions
北京海润天睿律师事务所关于北京诺思兰德生物技术股份有限公司2021年年度股东大会的法律意见书
Regulatory Filings
2022-05-17 Chinese
监事会主席任命公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the appointment of the chairman of the supervisory board (监事会主席) of Beijing Northland Biotech Co., Ltd. It details the election decision, the background of the appointee, and the impact of the appointment on the company. There is no financial data, no mention of financial results, no regulatory filings or certifications, and no reference to any report publication. The content clearly relates to changes in the company's board or senior management. Therefore, the document fits the category of Board/Management Information (MANG). The document length is short and focused solely on the appointment, confirming it is not a full report or announcement of a report publication.
2022-05-17 Chinese
投资者关系活动记录表
Call Transcript Classification · 95% confidence The document is titled as an "投资者关系活动记录表" (Investor Relations Activity Record) and describes a performance explanation meeting (业绩说明会) held on May 11, 2022, regarding the 2021 annual report. It includes detailed Q&A between investors and company management about clinical trials, financial performance, and company projects. The document is a transcript or record of an earnings explanation meeting rather than the actual annual report or earnings release. It is not a short announcement but a detailed record of the meeting. This fits the definition of a Call Transcript (CT) or Earnings Release (ER). However, since it is a detailed Q&A session with management explaining the annual report results, it aligns best with a Call Transcript (CT) of an earnings or annual report explanation meeting rather than a brief Earnings Release (ER). Therefore, the appropriate classification is Call Transcript (CT).
2022-05-11 Chinese
2021年度报告业绩说明会预告公告
AGM Information Classification · 95% confidence The document is a notice announcing a scheduled performance explanation meeting related to the company's 2021 Annual Report. It references the 2021 Annual Report but does not contain the report itself or detailed financial data. The document is short (901 characters) and serves to inform investors about the upcoming meeting where the report will be discussed. According to the 'Menu vs Meal' rule, this is an announcement about a report-related event, not the report itself. Therefore, the appropriate classification is AGM Information (AGM-R), as it pertains to materials shared during an Annual General Meeting or similar shareholder meeting event.
2022-05-05 Chinese
关于延期回复发行注册环节反馈意见落实函的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Beijing Northland Biotechnology Co., Ltd. regarding a delay in responding to feedback from the securities issuance registration process. It references regulatory bodies such as the Beijing Stock Exchange and the China Securities Regulatory Commission, and discusses procedural matters related to the issuance registration and updating financial data. The document is short (720 characters) and does not contain any financial statements or detailed financial data. It is an announcement about the status and timing of a regulatory response rather than the report or financial data itself. Therefore, it fits best as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2022-05-04 Chinese
2021年度股东大会通知公告 （提供网络投票）
AGM Information Classification · 95% confidence The document is a notice announcing the convening of the 2021 Annual General Meeting (AGM) of Beijing Northland Biotech Co., Ltd. It details the meeting date, voting methods (including online voting), agenda items to be discussed and voted on at the AGM, such as the 2021 annual reports, financial statements, appointment of auditors, amendments to company bylaws, and election of directors and supervisors. The document does not contain the actual reports or financial statements but references where these can be found. The document is primarily an announcement and invitation to shareholders to attend and vote at the AGM, including procedural details. Therefore, it fits the category of AGM Information (AGM-R). The document length (6918 characters) supports it being a detailed notice rather than a full report or transcript.
2022-04-25 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.